Discussion on the Effect of Shugan Lipi Prescription on Patients with Diarrhea-predominant Irritable Bowel Syndrome of Liver Stagnation and Spleen Deficiency Type from the Disorder of Bile Acid-Intestinal Flora Axis
10.13359/j.cnki.gzxbtcm.2025.01.014
- VernacularTitle:从胆汁酸-肠道菌群轴失调探讨疏肝理脾方对腹泻型肠易激综合征肝郁脾虚证患者的影响
- Author:
Ping LI
1
;
Xile YANG
;
Anqi ZHU
;
Ruiqing ZHANG
Author Information
1. 西安市第九医院消化科,陕西西安 710054
- Keywords:
disorder of bile acid-intestinal flora axis;
Shugan Lipi Prescription;
diarrhea-predominant irritable bowel syndrome;
liver stagnation and spleen deficiency type
- From:
Journal of Guangzhou University of Traditional Chinese Medicine
2025;42(1):94-100
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the effect of Shugan Lipi Prescription on patients with diarrhea-predominant irritable bowel syndrome(IBS-D)of liver stagnation and spleen deficiency type from the perspective of bile acid-intestinal flora axis imbalance.Methods From May 2022 to May 2023,a total of 122 patients with IBS-D of liver stagnation and spleen deficiency type admitted to the Xi'an No.9 Hospital were enrolled into the investigation.The patients were randomly divided into the control group and the observation group by random number table method,with 61 patients in each group.The control group was given conventional western medicine treatment with oral administration of Dicetel plus Compound Diphenoxylate Tablets and Bifidobacterium Quadruple Viable Tablets,and the observation group was treated with Shugan Lipi Prescription on the basis of treatment for the control group.One course of treatment covered seven days,and both groups were treated for four courses in total.The changes of Irritable Bowel Syndrome Symptom Severity Scale(IBS-SSS)score,levels of serum bile acid and the fecal levels of intestinal flora such as Bifidobacterium,Lactobacillus,and Enterococcus in the two groups of patients before and after treatment were observed.Moreover,the clinical efficacy and the incidence of adverse reactions during the treatment of the two groups were compared.Results(1)After four courses of treatment,the total effective rate of the observation group was 96.72%(59/61)and that of the control group was 83.61%(51/61),and the intergroup comparison(tested by chi-square test)showed that the efficacy of the observation group was significantly superior to that of the control group(P<0.05).(2)After treatment,the scores of IBS-SSS items such as abdominal pain,abdominal pain duration,abdominal distension,defecation satisfaction and life interference in the two groups were all decreased when compared with those before treatment(P<0.05),and the decrease in the observation group was significantly superior to that in the control group(P<0.01).(3)After treatment,the levels of serum taurodeoxycholic acid(TDCA),taurocholic acid(TCA)and taurolithocholic acid(TLCA)in the two groups were decreased when compared with those before treatment(P<0.05),and the decrease in the observation group was significantly superior to that in the control group(P<0.01).(4)After treatment,the fecal level of Enterococcus,a kind of pathogenic bacterium,in both groups was decreased when compared with that before treatment(P<0.05),and the fecal levels of probiotics of Bifidobacterium and Lactobacillus in both groups were increased when compared with those before treatment(P<0.05).The effects on the decrease of fecal Enterococcus level and on the increase of fecal Bifidobacterium and Lactobacillus levels in the observation group were significantly superior to those in the control group(P<0.05 or P<0.01).(5)The incidence of adverse reactions in the observation group was 8.20%(5/61)and that in the control group was 6.55%(4/61),and the intergroup comparison showed that the difference was not statistically significant(P>0.05).Conclusion Shugan Lipi Prescription exerts certain therapeutic effect for IBS-D patients of liver stagnation and spleen deficiency type,and is with higher safety.Its therapeutic mechanism may be related to the restoration of the function of bile acid-intestinal flora axis.
